{"entity":{"id":"nct07102004","kind":"trial","name":"Study of MHB088C for Patients With Advanced Solid Malignant Tumors","aka":[],"tldr":"A phase 1/2 trial of QLC5508 in advanced solid tumours, run by Qilu Pharmaceutical Co., Ltd., now recruiting.","summary":"Study of MHB088C for Patients With Advanced Solid Malignant Tumors is a phase 1/2 interventional study registered as NCT07102004 by Qilu Pharmaceutical Co., Ltd., with 515 participants planned, started 2023-06-20 and due to reach its primary completion in 2026-07. Interventions recorded: MHB088C for Injection.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07102004","url":"https://clinicaltrials.gov/study/NCT07102004"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["qlc5508"],"companies":["qilu-pharmaceutical"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07102004","phase":"1/2","setting":"A Phase I/II Study of MHB088C for Patients With Advanced Malignant Solid Tumors","sponsor":"Qilu Pharmaceutical Co., Ltd.","enrolled":515,"outcomes":[]},"route":"/trials/nct07102004/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"qlc5508","kind":"drug","name":"QLC5508","route":"/drugs/qlc5508/"}],"company":[{"id":"qilu-pharmaceutical","kind":"company","name":"Qilu Pharmaceutical","route":"/companies/qilu-pharmaceutical/"}]}}